Sienna signs licensing deal for cancer test
23 January, 2012 by Dylan Bushell-EmblingSienna Cancer Diagnostics has reached a new agreement with licensor Geron for the IP needed to continue development its telomerase protein detector tests.
Chardonnay genome project seeks to improve wine
20 January, 2012 by Tim DeanA joint effort by the Australian Wine Research Institute and the University of British Columbia will sequence 15 varieties of the world’s most popular wine grape.
vivoPharm signs oncology partner for US
19 January, 2012 by Dylan Bushell-EmblingSouth Australia's vivoPharm has arranged to co-market primary patient-derived tumours owned by Berlin's EPO to US cancer drug researchers.
Comment sought on "Enabling Technologies Roadmap"
19 January, 2012 by AusBiotechThe government is seeking comment on a new report covering the future of biotechnology and nanotechnology.
UQ, industry partner for rheumatoid arthritis treatment
18 January, 2012 by Dylan Bushell-EmblingUniQuest spinoff and pharmaceutical R&D company Janssen-Cilag will combine resources to support the development of a rheumatoid arthritis treatment.
Clinuvel trading at nine-month highs
17 January, 2012 by Dylan Bushell-EmblingClinuvel Pharmaceuticals’ (ASX:CUV) cites positive trial results for SCENESSE as likely reason for 34.2% spike in stock price last week.
Industry leaders to take part in annual industry position survey
17 January, 2012 by AusBiotechAusBiotech is pleased to once again conduct the annual CEO Industry Position Survey 2012, this year proudly supported by Grant Thornton.
Bootylicious fly named after Beyonce
13 January, 2012 by Tim DeanA new species of horse fly with a notably resplendent abdomen has been named after the American pop diva, Beyonce.
A new year, a new look and good news is rolling in already…
12 January, 2012 by AusBiotech2011 ended on a high for the Australian biotechnology industry, and 2012 is already off to a strong start for the sector.
Australian native plants found to have anti-microbial properties
12 January, 2012 by Staff WritersA Queensland collaborative research programme has found common native Australian plums can extend the shelf life of meat products.
Starpharma to advance with phase III studies for VivaGel
11 January, 2012 by Tim DeanPhase III trials of VivaGel to commence shortly after receiving FDA agreement on study design in anticipation of application for regulatory approval.
Bionomics scores deal worth up to US$345 million
11 January, 2012 by Tim DeanDeal with US pharmaceutical company Ironwood to develop anti-anxiety compound BNC210 could be worth up to US$345 million for the Adelaide-based biotech.
Feature: Fever pitch
23 December, 2011 by Fiona WylieProfessor Suresh Mahalingam and his team have made some intriguing discoveries that could lead to treatments of some nasty mosquito-borne diseases.
QRxPharma to form US sales partnership
21 December, 2011 by Dylan Bushell-EmblingDrug development company QRxPharma (ASX:QRX) has agreed to form a partnership with Actavis covering commercialisation of its lead product, MoxDuo, in the US market.
Viralytics raises $4.7m to fund melanoma trial
20 December, 2011 by Staff WritersCash levels boosted to over $8 million to help fund phase II melanoma trial.
